National Institute of Neurological Disorders and Stroke; Notice of Closed Meeting, 68507-68508 [2022-24824]
Download as PDF
<![CDATA[
Federal Register / Vol. 87, No. 219 / Tuesday, November 15, 2022 / Notices
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel; PAR22–069 High
Impact, Interdisciplinary Science in NIDDK
Research Areas: Adipocyte Heterogeneity
(RC2).
Date: December 6, 2022.
Time: 11:30 a.m. to 1:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
National Institute of Diabetes and Digestive
and Kidney Diseases, 2 Democracy, 6707
Democracy Blvd., Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Ann A Jerkins, Ph.D.,
Scientific Review Officer, Review Branch,
DEA, NIDDK, National Institutes of Health,
Room 7119, 6707 Democracy Boulevard,
Bethesda, MD 20892–5452, 301–594–2242,
jerkinsa@niddk.nih.gov.
Information is also available on the
Institute’s/Center’s home page:
www.niddk.nih.gov/, where an agenda and
any additional information for the meeting
will be posted when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.847, Diabetes,
Endocrinology and Metabolic Research;
93.848, Digestive Diseases and Nutrition
Research; 93.849, Kidney Diseases, Urology
and Hematology Research, National Institutes
of Health, HHS)
Dated: November 8, 2022.
Miguelina Perez,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2022–24731 Filed 11–14–22; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
lotter on DSK11XQN23PROD with NOTICES1
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
VerDate Sep<11>2014
19:16 Nov 14, 2022
Jkt 259001
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; NIAID Clinical Trial
Implementation Cooperative Agreement (U01
Clinical Trial Required).
Date: December 9, 2022.
Time: 9:00 a.m. to 12:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3G54,
Rockville, MD 20892 (Virtual Meeting).
Contact Person: Hitendra S. Chand, Ph.D.,
Scientific Review Officer, Scientific Review
Program, Division of Extramural Activities,
National Institute of Allergy and Infectious
Diseases, National Institutes of Health, 5601
Fishers Lane, Room 3G54, Rockville, MD
20852, (240) 627–3245, hiten.chand@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: November 8, 2022.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2022–24774 Filed 11–14–22; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Emerging
Imaging Technologies and Applications.
PO 00000
Frm 00071
Fmt 4703
Sfmt 4703
68507
Date: December 6, 2022.
Time: 9:00 a.m. to 2:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Lawrence Edward
Kagemann, Ph.D., Scientific Review Officer,
Center for Scientific Review, 6701 Rockledge
Drive, Bethesda, MD 20892, (301) 480–6849,
larry.kagemann@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: November 8, 2022.
Miguelina Perez,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2022–24729 Filed 11–14–22; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Neurological
Disorders and Stroke; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Neurological Disorders and Stroke Special
Emphasis Panel; NINDS Special Emphasis
Panel.
Date: December 5–6, 2022.
Time: 10:00 a.m. to 1:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852 (Virtual
Meeting).
Contact Person: Marilyn Moore-Hoon,
Ph.D., Scientific Review Officer, Scientific
Review Branch, Division of Extramural
Activities, NINDS/NIH, NSC, 6001 Executive
Boulevard, Bethesda, MD 20892, 301–827–
9087, mooremar@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.853, Clinical Research
E:\FR\FM\15NON1.SGM
15NON1
68508
Federal Register / Vol. 87, No. 219 / Tuesday, November 15, 2022 / Notices
Related to Neurological Disorders; 93.854,
Biological Basis Research in the
Neurosciences, National Institutes of Health,
HHS.)
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
comments in writing, or request more
information on the proposed project,
contact: Christeenna Iraheta, Office of
Administrative and Management
Analysis Services, National Library of
Medicine, Building 38A, Room
B2N12A, 8600 Rockville Pike, Bethesda,
MD 20894, or call non-toll-free number
(301) 827–6361, or Email your request,
including your address to:
Christeenna.iraheta@nih.gov. Formal
requests for additional plans and
instruments must be requested in
writing.
National Institutes of Health
SUPPLEMENTARY INFORMATION:
Dated: November 9, 2022.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2022–24824 Filed 11–14–22; 8:45 am]
BILLING CODE 4140–01–P
Proposed Collection; 60-Day Comment
Request Information Program on
Clinical Trials: Maintaining a Registry
and Results Databank (National Library
of Medicine)
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
In compliance with the
requirement of the Paperwork
Reduction Act of 1995 to provide
opportunity for public comment on
proposed data collection projects, the
National Library of Medicine (NLM),
National Institutes of Health (NIH), will
publish periodic summaries of proposed
projects to be submitted to the Office of
Management and Budget (OMB) for
review and approval.
DATES: Comments regarding this
information collection are best assured
of having their full effect if received
with 60 days of the date of this
publication.
FOR FURTHER INFORMATION CONTACT: To
obtain a copy of the data collection
plans and instruments, submit
SUMMARY:
Medicine (NLM), National Institutes of
Health (NIH).
Need and Use of Information
Collection: The National Institutes of
Health operates ClinicalTrials.gov,
which was established as a clinical trial
registry under section 113 of the Food
and Drug Administration Modernization
Act of 1997 (Pub. L. 105–115) and was
expanded to include a results data bank
by Title VIII of the Food and Drug
Administration Amendments Act of
2007 (FDAAA) and by the Clinical
Trials Registration and Results
Information Submission regulations at
42 CFR part 11. ClinicalTrials.gov
collects registration and results
information for clinical trials and other
types of clinical studies (e.g.,
observational studies and patient
registries) with the objectives of
enhancing patient enrollment and
providing a mechanism for tracking
subsequent progress of clinical studies
to the benefit of public health. It is
widely used by patients, physicians,
and medical researchers; in particular
those involved in clinical research.
While many clinical studies are
registered and submit results
information voluntarily, 42 CFR part 11
requires the registration of certain
applicable clinical trials of drug,
biological, and device products and the
submission of results information for
completed applicable clinical trials of
drug, biological, and device products
whether or not they are approved,
licensed, or cleared by the Food and
Drug Administration.
OMB approval is requested for 3
years. There are no costs to respondents
other than their time. The total
estimated annualized burden hours are
1,219,801.
Section
3506(c)(2)(A) of the Paperwork
Reduction Act of 1995 requires written
comments and/or suggestions from the
public and affected agencies are invited
to address one or more of the following
points: (1) Whether the proposed
collection of information is necessary
for the proper performance of the
function of the agency, including
whether the information will have
practical utility; (2) The accuracy of the
agency’s estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used; (3)
Ways to enhance the quality, utility, and
clarity of the information to be
collected; and (4) Ways to minimize the
burden of the collection of information
on those who are to respond, including
the use of appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology.
Proposed Collection Title: Information
Program on Clinical Trials: Maintaining
a Registry and Results Databank, 0925–
0586, Expiration Date: 02/28/2023,
EXTENSION, National Library of
ESTIMATED ANNUALIZED BURDEN HOURS
Number of
respondents
Submission type
Number of
responses per
respondent
Average
time per
response
(in hours)
Total annual
burden hours
Registration—attachment 2
lotter on DSK11XQN23PROD with NOTICES1
Initial .................................................................................................................
Updates ............................................................................................................
Triggered, voluntary .........................................................................................
Initial, non-regulated, NIH Policy .....................................................................
Updates, non-regulated, NIH Policy ................................................................
Initial, voluntary and non-regulated .................................................................
Updates, voluntary and non-regulated ............................................................
7,400
7,400
141
940
940
17,860
17,860
1
8
1
1
8
1
8
8
2
8
8
2
8
2
59,200
118,400
1,128
7,520
15,040
142,880
285,760
1
2
1
1
2
1
40
10
45
40
10
40
296,000
148,000
2,115
37,600
18,800
56,000
Results Information Submission—attachment 5
Initial .................................................................................................................
Updates ............................................................................................................
Triggered, voluntary—also attachment 2 ........................................................
Initial, non-regulated, NIH Policy .....................................................................
Updates, non-regulated, NIH Policy ................................................................
Initial, voluntary and non-regulated .................................................................
VerDate Sep<11>2014
19:16 Nov 14, 2022
Jkt 259001
PO 00000
Frm 00072
Fmt 4703
Sfmt 4703
7,400
7,400
47
940
940
1,400
E:\FR\FM\15NON1.SGM
15NON1
]]>Agencies
[Federal Register Volume 87, Number 219 (Tuesday, November 15, 2022)]
[Notices]
[Pages 68507-68508]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-24824]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Neurological Disorders and Stroke; Notice
of Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute of Neurological Disorders
and Stroke Special Emphasis Panel; NINDS Special Emphasis Panel.
Date: December 5-6, 2022.
Time: 10:00 a.m. to 1:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Neuroscience Center, 6001
Executive Boulevard, Rockville, MD 20852 (Virtual Meeting).
Contact Person: Marilyn Moore-Hoon, Ph.D., Scientific Review
Officer, Scientific Review Branch, Division of Extramural
Activities, NINDS/NIH, NSC, 6001 Executive Boulevard, Bethesda, MD
20892, 301-827-9087, [email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.853,
Clinical Research
[[Page 68508]]
Related to Neurological Disorders; 93.854, Biological Basis Research
in the Neurosciences, National Institutes of Health, HHS.)
Dated: November 9, 2022.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2022-24824 Filed 11-14-22; 8:45 am]
BILLING CODE 4140-01-P
